First Responder PTSD Presumptive Legislation in Canada — Provincial Comparison and Treatment Pathways (2026)

Canadian first responders diagnosed with PTSD (post-traumatic stress disorder) may qualify for workers' compensation benefits without proving their condition is work-related — because most provinces have enacted presumptive PTSD legislation that shifts the burden of proof to the board. This national guide compares current presumptive coverage across all ten provinces, explains what that coverage means for access to psychedelic-assisted therapy, and details the evidence for MDMA-AT (MDMA-assisted therapy), ketamine, and Health Canada's Special Access Program (SAP) in first-responder populations.

Key takeaways

• 44.5% of Canadian public safety personnel screen positive for at least one mental disorder; 23.2% screen positive specifically for PTSD — compared to 1.1–3.5% in the general population [Carleton et al. 2018].
• Every province except Quebec has some form of presumptive PTSD legislation for first responders or all workers. Coverage, covered occupations, and procedures vary significantly.
• Ontario (Bill 163, updated February 2026) covers firefighters, police, paramedics, corrections officers, 911 dispatchers, nurses, and wildland firefighters. A February 2026 WSIB policy overhaul revised the rebuttal process.
• Alberta (Bill 27, 2018) covers firefighters, paramedics, correctional officers, emergency dispatchers, and sheriffs. RCMP members employed by the federal government may not be covered.
• Saskatchewan and Manitoba provide the broadest coverage in Canada — all workers are eligible, not just first responders, and Saskatchewan covers all psychological injuries, not just PTSD.
• Presumptive legislation covers the PTSD diagnosis. Specific treatments — ketamine infusions, MDMA-assisted therapy via SAP — still require separate prior authorization or case-by-case review.
• MDMA-AT (Health Canada SAP) has the strongest published RCT evidence for PTSD in first-responder populations specifically [Mithoefer et al. 2018, Lancet Psychiatry]. SAP approval is case-by-case and is not guaranteed [PsyCan 2025].
• Spravato (esketamine) is approved by Health Canada for treatment-resistant depression (TRD) only — it is NOT approved for PTSD.

What is presumptive PTSD legislation and why it matters for first responders

Presumptive PTSD legislation shifts the legal burden of proof in workers' compensation claims. Without presumptive coverage, the injured worker must demonstrate on a balance of probabilities that their PTSD arose from and during the course of employment. For first responders, this was historically difficult: cumulative trauma exposure, underreporting culture, and the delayed onset of PTSD symptoms all complicated claim decisions. Presumptive legislation reverses this: once a first responder receives a formal PTSD diagnosis from a qualified psychologist or psychiatrist, the PTSD is automatically presumed to be work-related unless the workers' compensation board can demonstrate otherwise. This presumption does not guarantee approval of specific treatments. The underlying PTSD diagnosis receives accelerated adjudication; treatment prior authorization for specific interventions (such as ketamine infusions or MDMA-assisted therapy) follows a separate pathway. The practical value of presumptive legislation for accessing psychedelic-assisted therapy is that it removes the first barrier — the causal dispute about PTSD itself — so the worker and their care team can focus on documenting treatment history and building the prior-authorization case for the specific intervention.

For the full workers' compensation framework for psychedelic-assisted therapy in Canada, including WSIB Ontario's five specialty formularies covering ketamine and esketamine, see Workers' Compensation for Psychedelic-Assisted Therapy in Canada.

How common is PTSD among Canadian first responders?

The most comprehensive Canadian peer-reviewed data on first-responder mental health come from Carleton et al. (2018), a cross-sectional survey of 5,813 public safety personnel published in The Canadian Journal of Psychiatry. The study found that 44.5% of Canadian public safety personnel screened positive for at least one mental disorder, and 23.2% screened positive specifically for PTSD — compared to an estimated 1.1–3.5% in the general Canadian population [Carleton et al. 2018]. Occupational groups in the study included correctional workers, call-centre operators and dispatchers, firefighters, municipal and provincial police, paramedics, and RCMP. The researchers noted that "Canadian PSP experience substantial and heterogeneous difficulties with mental health" and that estimates appeared higher than previously published data for the general population. International evidence adds context: law enforcement officers develop PTSD at estimated rates of 6–32%, paramedics and EMTs at 9–22%, and firefighters at 17–32% [SAMHSA 2018]. These rates are compounded by moral injury — guilt, shame, and spiritual distress arising from acts that transgress one's moral beliefs (Litz et al. 2009) — which frequently co-occurs with PTSD and complicates treatment response. For a deeper discussion of moral injury in first responders and healthcare workers, see Burnout, Moral Injury, and Psychedelic-Assisted Therapy in Canada.

Cross-provincial comparison: which provinces have presumptive PTSD legislation

The table below summarizes the current (2026) status of presumptive PTSD or psychological-injury legislation across all Canadian provinces. This is an active area of policy change; first responders should verify current status with their provincial board.

Key insight: Saskatchewan provides the broadest coverage in Canada — all workers, and all forms of psychological injury, not only PTSD. Manitoba and Saskatchewan are the only provinces where a first responder in any role, or a worker in any other occupation, benefits from the presumption. Quebec is the significant outlier: no presumptive legislation means first responders who develop PTSD must prove on a balance of probabilities that the PTSD is work-related.

Watch out: Presumptive legislation does NOT mean specific treatments are automatically covered. A presumed PTSD diagnosis accelerates eligibility for workers' compensation benefits broadly; prior authorization for specific treatments (ketamine, MDMA-AT) is a separate step.

Ontario — Bill 163 and the February 2026 WSIB policy overhaul

Ontario's Bill 163 (Supporting Ontario's First Responders Act) was passed in 2016 and created a statutory presumption that PTSD diagnosed in designated first responders is work-related. Subsequent legislative amendments in October 2022 expanded eligibility to wildland firefighters and wildland fire investigators, with the effective date for eligibility set at October 28, 2022.

WSIB Policy 15-03-13 (effective February 4, 2026) is the current operative policy. The February 2026 update made two categories of change: it formally incorporated the wildland firefighter and wildland fire investigator expansion into WSIB operational policy, and it substantially revised the guidance on the rebuttal process — specifying when rebuttal should be considered during claims adjudication, which factors apply to the rebuttal determination, and what steps follow a successful rebuttal. First-responder advocates noted the rebuttal changes were implemented without stakeholder consultation and may affect claim outcomes [Compclaim Legal Services 2026].

Covered occupations under Ontario Bill 163 (current):

• Full-time, part-time, and volunteer firefighters
• Fire investigators
• Police officers
• Paramedics and emergency medical attendants
• Emergency-response telephone operators (911 dispatchers)
• Corrections officers
• Nurses providing direct patient care
• Wildland firefighters and wildland fire investigators (eligibility from October 28, 2022)

Diagnostic requirement: PTSD must be diagnosed by a psychologist or psychiatrist per DSM-5 criteria. Workers diagnosed within 24 months of ceasing employment may still qualify.

Rebuttal standard: The presumption can be rebutted only if evidence shows that employment "was not a significant contributing factor in causing" the PTSD. The February 2026 policy added granularity to how this rebuttal evidence is assessed.

For WSIB ketamine and esketamine formulary details (the treatment coverage side), see the Workers' Compensation for Psychedelic-Assisted Therapy parent hub.

Alberta — Bill 27 and the WCB pharmaceutical procedure

Alberta enacted Bill 27 (Workers' Compensation Amendment Act 2018) to create presumptive PTSD coverage for first responders. Section 24.2 of the Workers' Compensation Act establishes the presumption: if a first responder, correctional officer, emergency dispatcher, or a member of any other class of worker prescribed by regulations is or has been diagnosed with PTSD by a physician or psychologist, the PTSD is presumed, unless the contrary is proven, to be an injury that arose out of and occurred in the course of employment.

Important note on RCMP: RCMP members are federal employees and their workers' compensation pathway falls under the Government Employees Compensation Act (federal), not provincial WCB coverage. The Alberta Bill 27 presumption may not apply to federally-employed RCMP officers in the same way it applies to municipal and provincial police. RCMP members should verify coverage with the federal employer or a workers' compensation advocate.

Covered under Bill 27 (confirmed):

• Firefighters
• Paramedics and emergency medical technicians
• Sheriffs
• Municipal and provincial police officers
• Correctional officers
• Emergency dispatchers

WCB Alberta also maintains a Pharmaceutical Ketamine and Esketamine procedure covering compensable PTSD (among other conditions). This means a first responder who successfully establishes a compensable PTSD claim under Bill 27 may be eligible for ketamine therapy as treatment — subject to prior-authorization criteria documenting prior treatment failures. WCB Alberta does not have a formal listing for MDMA-assisted therapy; case-by-case review may apply.

Despite the legislation, advocates report that some claims continue to be denied or delayed. Of 792 psychological-injury claims filed by Alberta first responders in 2021, 227 were denied by WCB [Wayfinders Wellness Society, cited in Canadian Occupational Safety]. This underscores the importance of thorough documentation when building a claim.

British Columbia — expanded June 2024

BC's mental-health presumption has been progressively expanded since 2018. The 2018 Workers Compensation Act amendments created the original presumption for firefighters, police, paramedics, sheriffs, and correctional officers. A 2019 regulatory expansion added emergency response dispatchers, nurses, publicly funded health-care assistants, forest firefighters, and fire investigators.

The most recent expansion — effective June 10, 2024 — added 11 new occupations: community-integration specialists, coroners, harm-reduction workers, parole officers, probation officers, respiratory therapists, shelter workers, social workers, transition house workers, victim service workers, and withdrawal-management workers. This makes BC's coverage among the broadest in Canada in terms of occupational scope.

BC's presumption covers mental disorders broadly, not only PTSD — which means first responders in BC with other work-related psychological injuries may also benefit.

WorkSafeBC does not have a formal formulary listing for ketamine or MDMA-AT comparable to WSIB Ontario. Treatment coverage follows a case-by-case evidence-based review process. WorkSafeBC's Evidence-Based Practice Group published a 2025 update on IV and oral ketamine for chronic non-cancer pain.

Saskatchewan, Manitoba, and Atlantic provinces

Saskatchewan (2016) covers all workers — not only first responders — and uniquely covers all forms of psychological injury, not only PTSD. Saskatchewan is the most inclusive province in terms of both occupational and diagnostic scope. Workers' compensation psychological injury claims in Saskatchewan are assessed under a traumatic-events framework.

Manitoba (effective January 1, 2016) extended presumptive coverage to all workers, recognizing that PTSD-triggering events can happen in any workplace, not only in first-responder roles.

New Brunswick (2016) covers firefighters, paramedics, and police officers (with RCMP members excluded from the presumption, as RCMP are federal employees).

Nova Scotia (effective October 26, 2018) covers eight occupational categories: correctional officers, emergency-response dispatchers, firefighters (municipal and federal, paid and volunteer), nurses, paramedics, police officers, sheriffs, and continuing-care assistants. There is no time limit between leaving employment and filing a claim; workers have five years from diagnosis to submit.

Newfoundland and Labrador and Prince Edward Island have presumptive coverage for all workers according to Canadian Labour Congress summaries. Specific provisions should be verified directly with WCB NL (1-800-563-9000) and WCB PEI (1-800-237-5049).

Quebec (CNESST) — no presumptive legislation. Quebec remains the only province without presumptive PTSD legislation for first responders. Workers in Quebec who develop PTSD must demonstrate on a balance of probabilities that the PTSD is work-related. If appealed to the Tribunal administratif du travail (TAT), the burden of proof is on the worker [McGill Journal of Law and Health 2018]. Quebec first responders with PTSD may pursue CNESST claims through standard processes, but the absence of a presumption makes the initial adjudication more challenging.

Why MDMA-assisted therapy is the headline evidence for first-responder PTSD

The evidence for MDMA-assisted therapy (MDMA-AT) in first-responder and veteran populations is the strongest of any psychedelic therapy specifically in these occupational groups.

Mithoefer et al. 2018 (Lancet Psychiatry): A phase 2 randomized, double-blind, dose-response trial enrolled 26 participants — 22 military veterans, 3 firefighters, and 1 police officer — with chronic PTSD. The high-dose MDMA groups (75 mg and 125 mg) showed significantly greater reductions in PTSD severity than the active control (30 mg) group. At 12-month follow-up, mean CAPS-IV total score had decreased from 87.1 to 38.8 (p less than 0.0001). One month after the second dosing session, 68% of full-dose participants no longer met PTSD diagnostic criteria, compared to 29% in the low-dose control group [Mithoefer et al. 2018].

Mitchell et al. 2021 (Nature Medicine, MAPP1): A phase 3 randomized, double-blind, placebo-controlled trial in adults with severe PTSD (n=90). At 18 weeks, 67% of MDMA-group participants no longer met PTSD diagnostic criteria, compared to 32% in the placebo-plus-therapy group (Cohen's d=0.91; p less than 0.0001) [Mitchell et al. 2021].

Mitchell et al. 2023 (Nature Medicine, MAPP2): The confirmatory phase 3 trial in adults with moderate to severe PTSD replicated MAPP1 findings, further establishing the evidence base for MDMA-AT [Mitchell et al. 2023].

FDA and Canadian status: In August 2024, the U.S. FDA issued a Complete Response Letter (CRL) to Lykos Therapeutics declining to approve MDMA-AT for PTSD, citing concerns about data durability, safety, and trial methodology. The CRL was made public in September 2025. Lykos is preparing an additional phase 3 trial; a resubmission would likely place FDA approval in the late 2020s or early 2030s at the earliest. The FDA CRL does not affect Health Canada's Special Access Program (SAP). MDMA-AT remains accessible in Canada through SAP on a case-by-case basis — though PsyCan documented a sharp decline in Health Canada SAP approvals in September 2025 under the current government [PsyCan 2025]. Approval is not guaranteed.

For deep detail on MDMA-AT evidence and the SAP pathway, see MDMA-Assisted Therapy for PTSD and MDMA-Assisted Therapy for Veterans.

Key stat: Mithoefer et al. 2018 is the only phase 2 RCT of MDMA-AT specifically designed for and conducted in military veterans, firefighters, and police officers — making it the most directly relevant published evidence for this population.

Ketamine for first-responder PTSD: the accessible pathway

Off-label ketamine is the more practically accessible treatment pathway for first responders with compensable PTSD, for two reasons: it does not require a Health Canada SAP application, and it has formal workers' compensation coverage at WSIB Ontario and WCB Alberta.

Evidence: Feder et al. (2014) published the first randomized, controlled trial of IV ketamine for chronic PTSD (n=41), demonstrating rapid acute symptom reduction following a single infusion compared to an active placebo (midazolam). A follow-up RCT by Feder et al. (2021) examined six infusions over two weeks in 30 adults with chronic PTSD: 67% of the ketamine group were treatment responders compared to 20% in the midazolam group [Feder et al. 2021]. Albott et al. (2018) conducted an open-label study of six ketamine infusions in 15 military veterans with comorbid PTSD and treatment-resistant depression: 80% were in remission from PTSD symptoms at 14 days post-treatment; 40% maintained remission at 56 days [Albott et al. 2018].

Spravato (esketamine) — NOT for PTSD: Health Canada approved Spravato (esketamine nasal spray) in May 2020 for treatment-resistant depression (TRD) in adults. It is not approved for PTSD. Patients and clinicians should be cautious about any framing of Spravato as a PTSD treatment.

Ketamine is off-label for PTSD. Its use for PTSD is regulated by provincial medical regulators: the College of Physicians and Surgeons of Alberta (CPSA, March 2026 guidance update), the College of Physicians and Surgeons of Ontario (CPSO), and the College of Physicians and Surgeons of British Columbia (CPSBC), among others. The prescribing physician bears responsibility for off-label prescribing decisions.

Effect sizes: Ketamine's published effect sizes for PTSD are smaller and less consistent than for treatment-resistant depression. The Mithoefer and Mitchell MDMA-AT data (Cohen's d=0.91 in MAPP1) substantially exceed the ketamine PTSD evidence. Clinicians and patients should have realistic expectations.

For substance-specific detail, see Ketamine Therapy for PTSD.

Moral injury and why it complicates first-responder PTSD treatment

Moral injury is the lasting psychological, biological, spiritual, behavioural, and social impact of perpetrating, failing to prevent, or witnessing acts that transgress one's moral beliefs and expectations [Litz et al. 2009]. It is distinct from PTSD — which is anchored in fear-based threat responses — though the two conditions frequently co-occur in first-responder populations. Police officers, paramedics, corrections officers, and firefighters face cumulative exposure to traumatic events over careers measured in decades, creating conditions where both fear-based PTSD and values-based moral injury can develop concurrently.

The relevance for psychedelic-assisted therapy is specific: MDMA-AT, by reducing fear-based reactivity and fostering empathy and self-compassion during the therapeutic session, may support processing of moral-injury-related guilt and shame in ways that standard trauma-focused therapies such as Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE) do not directly target. The MAPS bulletin on moral injury and MDMA-AT describes this mechanism as relevant for this population. Moral injury treatment approaches — including Adaptive Disclosure (Litz et al. 2017) and Building Spiritual Strength — represent complementary, not competing, approaches to psychedelic-assisted therapy in this population.

For a broader discussion, see Burnout, Moral Injury, and Psychedelic-Assisted Therapy in Canada.

What evidence to submit with your workers' compensation claim

For first responders with presumptive PTSD coverage pursuing psychedelic-assisted therapy under workers' compensation, the following documentation is typically required. Verify specific requirements with your provincial board and a workers' compensation advocate or legal representative.

Step 1: Establish the presumptive PTSD diagnosis

• Formal PTSD diagnosis from a licensed psychologist or psychiatrist (not a general practitioner or other clinician) using DSM-5 criteria
• Documentation of occupational history confirming you worked in a designated occupation for at least one day on or after the relevant eligibility date
• Any documentation of specific traumatic events or cumulative trauma exposure (WSIB, WCB, and other boards may request this)

Step 2: Document conventional treatment failures

• Records of prior PTSD treatments: trauma-focused cognitive behavioural therapy (CPT, Prolonged Exposure), EMDR, SSRIs (sertraline, paroxetine), SNRIs, and other first-line interventions
• Duration of prior treatments and documented inadequate response
• Psychiatrist or physician letters summarizing prior treatment course

Step 3: Build the treatment plan for the specific intervention

• For ketamine: prescribing physician's treatment plan; documentation of PTSD diagnosis and prior treatment failures; CPSA (AB) or CPSO (ON) compliance with applicable provincial prescribing guidance
• For MDMA-AT via SAP: Health Canada SAP application by the prescribing physician (separate process); SAP approval must precede workers' compensation reimbursement request
• For esketamine (Spravato): only applicable if the first responder also has a concurrent TRD diagnosis (Spravato is NOT covered for PTSD as a standalone indication)

Step 4: Submit to your board

• WSIB Ontario: prior-authorization request to the Psychotraumatic (22WS) formulary for compensable PTSD
• WCB Alberta: Pharmaceutical Ketamine and Esketamine procedure; clinical justification required
• Other provinces: case-by-case review; no formal listing comparable to WSIB/WCB AB
• Appeal rights: denied prior authorizations can be appealed; additional specialist documentation typically supports appeals

Pro tip: First responders in Ontario should confirm whether they fall under the February 2026 updated rebuttal policy. The changes affect how claims adjudicated under the new policy handle the presumption-rebuttal question. A workers' compensation advocate or the Office of the Worker Adviser (Ontario) can help interpret the new policy's application to your claim.

How ATMA CENA supports first responders through the claim and treatment process

ATMA CENA's role for first responders with compensable PTSD is to provide clinical support from initial information through treatment planning and integration. Key aspects:

Treatment planning: For first responders pursuing ketamine-assisted therapy, ATMA CENA coordinates with the prescribing physician to align the treatment plan with the documentation requirements of the relevant workers' compensation board. For MDMA-AT via SAP, ATMA CENA's clinical team can support the prescribing physician's SAP application process.

Three-phase therapy model: Preparation, dosing, and integration — the standard psychedelic-assisted therapy framework. For first responders with co-occurring moral injury, the integration phase specifically addresses moral-injury dimensions with appropriate psychotherapy approaches.

Care coordination: For first responders with established therapeutic relationships (union-provided counsellors, EAP therapists, VAC-affiliated psychologists), ATMA CENA's care coordination model allows the existing therapist to remain the primary therapeutic relationship while ATMA CENA's clinical infrastructure provides the dosing-specific frame. This is particularly valuable for first responders who have built trust with an existing trauma clinician.

Veterans and dual-pathway cases: Some first responders are also Canadian Armed Forces veterans or RCMP members, creating potential overlap between workers' compensation and Veterans Affairs Canada (VAC) pathways. ATMA CENA's intake screens for both pathways and can orient the patient to the more appropriate — or complementary — funding source. For the VAC pathway specifically, see VAC Coverage for Psychedelic-Assisted Therapy.

Frequently asked questions

Does presumptive PTSD legislation mean my workers' compensation board automatically covers psychedelic-assisted therapy?

No. Presumptive PTSD legislation covers the underlying PTSD diagnosis — it shifts the burden of proving work-relatedness to the board. Specific treatments, including ketamine, MDMA-assisted therapy, and Spravato, still require separate prior authorization or case-by-case review. WSIB Ontario and WCB Alberta have formal listings for ketamine and esketamine; other provinces review case-by-case. Psilocybin and MDMA-AT are not formally listed on any Canadian workers' compensation formulary; MDMA-AT requires a Health Canada SAP application.

Which province has the strongest presumptive PTSD coverage for first responders?

Saskatchewan covers all workers and all forms of psychological injury — not only PTSD and not only first responders. Manitoba similarly covers all workers for PTSD. For first-responder-specific coverage, Ontario and BC have the most extensive occupational lists, particularly after Ontario's October 2022 expansion and BC's June 2024 expansion to 11 new occupations.

Does the Alberta WCB Bill 27 presumption cover RCMP officers?

Likely not directly. RCMP members are federal employees and fall under the Government Employees Compensation Act (federal) rather than provincial workers' compensation legislation. RCMP members with PTSD should contact the RCMP Veterans Association, the Office of the Correctional Investigator, or a workers' compensation advocate familiar with federal pathways to clarify their specific coverage. Municipal and provincial police officers in Alberta are covered under Bill 27.

What's the difference between MDMA-assisted therapy and ketamine for first-responder PTSD?

MDMA-AT has the strongest published phase 3 RCT evidence for PTSD and is the only treatment specifically tested in a phase 2 RCT that enrolled veterans, firefighters, and police officers [Mithoefer et al. 2018, Lancet Psychiatry]. However, MDMA-AT requires a Health Canada SAP application, which is case-by-case and not guaranteed, with approval timelines of several weeks to months. Ketamine is more accessible (no SAP required), has formal workers' compensation listings in Ontario and Alberta, and has documented PTSD efficacy in RCTs [Feder et al. 2014, 2021] — but effect sizes are smaller than for MDMA-AT.

Is Spravato (esketamine) an option for first responders with PTSD?

Spravato is not approved by Health Canada for PTSD. It is approved for treatment-resistant depression (TRD) only. If a first responder has both a PTSD diagnosis and a concurrent TRD diagnosis, Spravato may be applicable for the TRD component — but it should not be framed as a PTSD-specific treatment.

What happened with the FDA and MDMA therapy?

In August 2024, the U.S. FDA declined to approve MDMA-assisted therapy for PTSD, issuing a Complete Response Letter (CRL) to Lykos Therapeutics citing concerns about data durability, safety, and trial methodology. Lykos is planning an additional phase 3 trial with FDA input; a resubmission would take several years. This FDA decision does not affect Health Canada's Special Access Program. MDMA-AT remains accessible in Canada through SAP for patients who meet eligibility criteria, though Health Canada approvals declined sharply in 2025 [PsyCan 2025].

What is Quebec's position on presumptive PTSD for first responders?

Quebec (CNESST) has no presumptive PTSD legislation as of 2026. Workers in Quebec must prove on a balance of probabilities that their PTSD is work-related. If a claim is disputed and goes to the Tribunal administratif du travail (TAT), the burden of proof remains with the worker. Quebec firefighters, paramedics, and police officers with work-related PTSD can still pursue CNESST claims — they simply do not have the benefit of a presumption that other provinces provide.

How does a first responder start the process of accessing psychedelic-assisted therapy through workers' compensation?

The sequence: (1) Obtain a formal PTSD diagnosis from a licensed psychologist or psychiatrist using DSM-5 criteria. (2) File a workers' compensation claim; document your designated occupation and service period to trigger the presumption. (3) Gather prior treatment history documentation. (4) Work with a prescribing physician to develop a treatment plan for the specific intervention (ketamine, Spravato for TRD comorbidity, or MDMA-AT via SAP). (5) Submit prior-authorization request to your provincial board. (6) If denied, exercise appeal rights. A workers' compensation advocate and an experienced clinician are valuable throughout this process.

Can family members or spouses be involved in treatment?

Some MDMA-AT protocols have studied couples-therapy-structured approaches (Monson 2020 ARROW protocol). Standard ketamine and MDMA-AT protocols are individual-patient focused. Family involvement in the preparation and integration phases is supported at ATMA CENA and can be discussed during the information call.

Is MDMA-AT safe for first responders who have been on SSRIs or SNRIs?

This is a clinical question that must be addressed by the prescribing physician. MDMA has documented interactions with SSRIs and SNRIs; a washout period is typically required before MDMA-AT sessions. Patients should not discontinue antidepressants without medical supervision. A comprehensive medication review is part of ATMA CENA's intake process.

Compliance disclaimer

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy is available only through Health Canada's Special Access Program (SAP). SAP approval is granted on a case-by-case basis and is not guaranteed. Psilocybin SAP is primarily approved for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness. MDMA SAP is primarily approved for adults with PTSD.

Ketamine is approved by Health Canada as an anaesthetic. Use for PTSD and other mental-health indications is off-label, regulated by provincial medical regulators — the College of Physicians and Surgeons of Alberta (CPSA), the College of Physicians and Surgeons of Ontario (CPSO), the College of Physicians and Surgeons of British Columbia (CPSBC), and other provincial colleges.

Spravato (esketamine) is approved by Health Canada for treatment-resistant depression (TRD) only. It is not approved for PTSD.

No psychedelic-assisted therapy is Health Canada-approved for PTSD. This article describes current evidence and access pathways for informational purposes only and does not constitute medical or legal advice. Workers' compensation coverage decisions are made by individual provincial boards on a case-by-case basis. Coverage for specific treatments is not guaranteed. First responders should consult their prescribing physician, provincial workers' compensation board, and a qualified workers' compensation advocate for guidance specific to their situation.

Sources

1. Carleton RN, Afifi TO, Turner S, et al. (2018). Mental Disorder Symptoms among Public Safety Personnel in Canada. Canadian Journal of Psychiatry, 63(1):54-64. PMID: 28845686. https://pubmed.ncbi.nlm.nih.gov/28845686/
2. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795. https://pubmed.ncbi.nlm.nih.gov/33972795/
3. Mitchell JM, Ot'alora GM, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473-2480. PMID: 37709999. https://pubmed.ncbi.nlm.nih.gov/37709999/
4. Mithoefer MC, Mithoefer AT, Feduccia AA, et al. (2018). MDMA-assisted psychotherapy for PTSD in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry, 5(6):486-497. PMID: 29728331. https://pubmed.ncbi.nlm.nih.gov/29728331/
5. Feder A, Parides MK, Murrough JW, et al. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry, 71(6):681-8. PMID: 24515513. https://pubmed.ncbi.nlm.nih.gov/24515513/
6. Feder A, Costi S, Rutter SB, et al. (2021). A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. American Journal of Psychiatry, 178(2):193-202. PMID: 33387447. https://pubmed.ncbi.nlm.nih.gov/33387447/
7. Albott CS, Lim KO, Forbes MK, et al. (2018). Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. Journal of Clinical Psychiatry, 79(3). https://pubmed.ncbi.nlm.nih.gov/29701934/
8. Litz BT, Stein N, Delaney E, et al. (2009). Moral injury and moral repair in war veterans: a preliminary model and intervention strategy. Clinical Psychology Review, 29(8):695-706. PMID: 19683376. https://pubmed.ncbi.nlm.nih.gov/19683376/
9. WSIB Ontario — Posttraumatic Stress Disorder in First Responders and Other Designated Workers (Policy 15-03-13, effective February 4, 2026). https://www.wsib.ca/en/operational-policy-manual/posttraumatic-stress-disorder-first-responders-and-other-designated
10. WSIB Ontario — Drug Formulary Listing Decision: Ketamine and Esketamine. https://www.wsib.ca/en/drug-formulary-listing-decision-ketamine-and-esketamine
11. WCB Alberta — Presumptive Coverage for Traumatic Psychological Injuries (Employer Fact Sheet). https://www.wcb.ab.ca/assets/pdfs/employers/EFS_Presumptive_coverage_for_traumatic_psychological_injuries.pdf
12. WCB Alberta — Pharmaceutical Ketamine and Esketamine. https://www.wcb.ab.ca/about-wcb/procedures-manual/pharmaceutical-ketamine-and-esketamine.html
13. WorkSafeBC — Mental health presumption extended to 11 new occupations (June 2024). https://www.worksafebc.com/en/about-us/news-events/announcements/2024/June/mental-health-presumption-extended-to-11-new-occupations
14. Nova Scotia — PTSD Presumption for Frontline or Emergency Response Workers. https://novascotia.ca/presumptive-ptsd/
15. Health Canada — Special Access Program: Requests involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
16. PsyCan (2025). PsyCan Discovers Sharp Decline in Health Canada Approvals for Doctors Seeking Legal Psychedelic Therapy for Patients. https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
17. CPSA — Ketamine Prescribing, Administration and Oversight Expectations (March 2026). https://cpsa.ca/wp-content/uploads/2026/03/CPSA_Ketamine-Guidance_March-2026.pdf
18. Compclaim Legal Services (2026). WSIB Presumptive PTSD in First Responders Policy Undergoes Overhaul Without Stakeholder Consultation. https://www.compclaim.com/2026/02/wsib-presumptive-ptsd-in-first-responders-policy-undergoes-overhaul-without-stakeholder-consultation/
19. SAMHSA (2018). First Responders: Behavioral Health Concerns, Emergency Response, and Trauma. https://www.samhsa.gov/sites/default/files/dtac/supplementalresearchbulletin-firstresponders-may2018.pdf

Related articles

• Workers' Compensation for Psychedelic-Assisted Therapy in Canada — cross-provincial WCB overview
• PTSD and Psychedelic-Assisted Therapy in Canada — PTSD condition and treatment overview
• VAC Coverage for Psychedelic-Assisted Therapy — for veterans (overlap with first responders)
• MDMA-Assisted Therapy for PTSD — MDMA-AT evidence and access
• MDMA-Assisted Therapy for Veterans — MDMA-AT in veteran populations
• Ketamine Therapy for PTSD — ketamine evidence and access for PTSD
• Burnout, Moral Injury, and Psychedelic-Assisted Therapy in Canada — moral injury and burnout in first responders and healthcare workers

Last updated: 2026-05-06. This article is reviewed every 3 months given active regulatory and legislative change in this area.